Business Context and Reporting Period
Company: Fresenius Medical Care AG & Co. KGaA
Filing Type: Form 6-K (Interim Report)
Reporting Period: Three and nine months ended September 30, 2017
Accounting Standard: IFRS (Euro reporting currency)
Overview: The world's largest kidney dialysis company, providing dialysis care, products, and "Care Coordination" services (pharmacy, vascular, physician services) in over 120 countries. The company operates four geographic segments: North America, EMEA, Asia-Pacific, and Latin America.
Key Financial Metrics (Nine Months Ended Sept 30, 2017)
| Metric | 2017 (€ millions) | 2016 (€ millions) | Change |
|---|---|---|---|
| Total Revenue | 13,355 | 12,153 | +10% |
| Operating Income | 1,843 | 1,679 | +10% |
| Operating Margin | 13.8% | 13.8% | Stable |
| Net Income (Shareholders) | 886 | 781 | +13% |
| Basic EPS | €2.89 | €2.56 | +13% |
| Free Cash Flow | 1,050 | 502 | +109% |
| Net Debt | 6,933 | 7,423 | -7% |
| Debt/EBITDA Ratio | 2.3x | 2.6x | Improved |
Material Changes vs. Prior Period
- Revenue Growth: Driven by organic revenue per treatment growth (+4%), same-market treatment growth (+3%), and acquisitions (+2%). A significant one-time reimbursement of approximately €96 million from the U.S. Department of Veterans Affairs (VA Agreement) contributed to the increase.
- Segment Performance:
- North America: Revenue +10%, Operating Income +10%. Care Coordination revenue surged 30% due to expanded participation in ESCO and shared savings programs.
- EMEA: Revenue +6%, but Operating Income declined 6% due to unfavorable currency effects, acquisition impacts (Xenios), and reimbursement pressure.
- Asia-Pacific: Revenue +12%, Operating Income +17%, driven by acquisitions in Australia and growth in China.
- Latin America: Revenue +15%, Operating Income +6%, with strong organic revenue growth offset by currency headwinds.
- Costs: Gross profit margin increased 0.4 percentage points. SG&A expenses as a percentage of revenue increased 0.4 percentage points, primarily due to higher bad debt and personnel costs in North America.
- Unusual Items: The period included "Natural Disaster Costs" of approximately €12 million (net of tax impact) and the aforementioned VA Agreement reimbursement.
Guidance, Outlook, and Risks
2017 Full-Year Outlook
Management confirmed its 2017 targets (excluding VA Agreement and Natural Disaster Costs):
- Revenue Growth: 8% – 10% (Constant Currency)
- Net Income Growth: 7% – 9% (Constant Currency); Management anticipates being at the low end of this range.
- Capital Expenditures: ~€0.9 billion
- Acquisitions: ~€0.6 billion
- Debt/EBITDA: < 2.5x
Key Risks and Contingencies
- Regulatory & Reimbursement: Ongoing uncertainty regarding U.S. Medicare reimbursement rates (ESRD PPS) and potential changes to the Affordable Care Act. A preliminary injunction remains in place blocking a CMS rule that would have negatively impacted patient insurance coverage via the American Kidney Fund.
- Legal Investigations:
- FCPA: Substantially concluded internal investigations into potential Foreign Corrupt Practices Act violations; discussions with U.S. government agencies are ongoing.
- Product Liability: Reached an agreement in principle to settle GranuFlo/NaturaLyte litigation for $250 million (€220 million funded by insurers, €60 million net expense accrued).
- False Claims Act: Multiple active investigations regarding billing practices, joint ventures, and pharmacy services.
- Currency: Significant exposure to foreign exchange fluctuations, particularly the Euro vs. U.S. Dollar, which negatively impacted reported results.
Investor Verification Checklist
- VA Agreement Impact: Verify the sustainability of the €96 million one-time reimbursement from the U.S. Department of Veterans Affairs and its exclusion from forward-looking guidance.
- Legal Settlements: Confirm the final funding and closure of the GranuFlo/NaturaLyte product liability settlement and the status of ongoing FCPA and False Claims Act investigations.
- Reimbursement Rates: Monitor CMS final rules for 2018 ESRD PPS rates and any legislative changes to the Affordable Care Act affecting Medicare Advantage plans.
- Currency Hedging: Assess the company's hedging strategy given the significant negative impact of currency translation on reported revenue and operating income.
- Acquisition Integration: Review the integration progress and margin contribution of recent acquisitions, specifically Xenios (non-dialysis products) and the Australia-based Care Coordination assets.